Royalty Report: Drugs, Cancer, Therapeutic – Collection: 27478

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Vaccine
  • Pharmaceuticals
  • Biotechnology
  • Disease
  • Viral Infection
  • Drug Discovery
  • Delivery
  • Diagnostic
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27478

License Grant
The Company acquired a new patented T-cell Modulation Process which uses heteroconjugates to direct the body to choose a specific immune response.
License Property
The heteroconjugate technology is intended to selectively stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections and cancer, when it cannot do so on its own.   Administered like vaccines, heteroconjugates combine T-cell binding ligands with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases – clinical studies.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 344581

License Grant
The University grants a worldwide, exclusive license under Licensed Subject Matter to manufacture, have manufactured, use, import, offer for sale and/or sell Licensed Products for use within Field.
License Property
The University owns certain Patent Rights and Technology Rights related to Licensed Subject Matter.

The licensed patents include
— Antibodies and Peptides Binding to Anionic Phospholipids and Aminophospholipids and Their Use in Viral Inhibition & Disease Treatment,
— Methods For Treating Viral Infections Using Antibodies To Aminophospholipids,
— Combinations and Kits for Treating Viral Infections Using Antibodies to Aminophospholipids,
— Methods for Treating Viral Infections Using Immunoconjugates to Aminophospholipids,
— Compositions for Treating Viral Infections Using lmmunoconjugates to Aminophospholipids,
— Combinations and Kits for Treating Viral Infections Using Immunoconjugates To Aminophospholipids,
— Selected Antibodies and Duramycin Peptides Binding to Anionic Phospholipids and Aminophospholipids and Their Use in Treating Viral Infections and Cancer,
— Selected Antibody Compositions For Binding To Aminophospholipids,
— Selected Antibody Compositions and Methods For Binding To Aminophospholipids,
— Cancer Treatment Methods Using Selected Antibodies to Aminophospholipids,
— Combined Cancer Treatment Methods Using Selected Antibodies to Aminophospholipids,
— Selected Antibody CDRs for Binding To Aminophospholipids,
— Liposomes Coated with Selected Antibodies That Bind to Aminophospholipids,
— Combinations and Kits For Cancer Treatment Using Selected Antibodies to Aminophospholipids,
— Selected Immunoconjugates for Binding To Aminophospholipids,
— Cancer Treatment Methods Using Selected Immunoconjugates For Binding To Aminophospholipids,
— Selected Antibodies & Duramycin Peptides Binding to Anionic Phospholipids & Aminophospholipids &
Their Use in Treating Viral Infections & Cancer,
— Compositions Comprising Cell-Impermeant Duramycin Derivatives,
— Anti-Viral Treatment Methods Using Phosphatidylethanolamine-Binding Peptide Derivatives,
— Compositions Comprising Phosphatidylethanolamine-Binding Peptides Linked to Anti-Viral Agents, and,
— Anti-Viral Treatment Methods Using Phosphatidylethanolamine-Binding Peptides Linked to Anti-Viral Agents.

Field of Use
The Field means all human therapeutic and diagnostic uses; and the treatment of viral infections and cancer.

IPSCIO Record ID: 310513

License Grant
The Foundation conducted a clinical study for the Company for two phase II clinical trials to determine if a vaccine containing AE37 plus GM-CSF or another peptide vaccine compound (GP2) plus GM-CSF improved patient outcomes. Pursuant to the Forbearance Agreement, the Company and the Foundation in exchange for the Foundations deferring the Company’s overdue payments, future payments and interest, the Company agreed, among other things to pay the Foundation certain royalties and accelerated payments.
License Property
AE37 (Ii-Key-HER2/neu peptide immunotherapeutic vaccine) is an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.

Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. T cells recognize antigenic epitopes when they are ‘presented’ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells, stimulating a multicellular cascade of actions that eliminates the diseased cell and protects against future disease recurrence.

In 2006 Phase I clinical trial was completed of AE37 in breast cancer, including a phase Ib safety and immunology study of AE37 in combination with GM-CSF in 16 breast cancer patients who had completed all first-line therapies and who were disease-free at the time of enrollment to the study (Holmes et al. Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;263426-33).

The Foundation conducted the study, under the sponsorship of an institute affiliated with the United States Military until the IND #12229 was transferred to the Company, after which Foundation continued trial management on behalf of the Company.

The Foundation is a nonprofit organization dedicated to advancing medicine by administering, managing and supporting preeminent scientific programs.

Field of Use
AE37 (Ii-Key-HER2/neu peptide immunotherapeutic vaccine) is for the treatment of breast cancer.

Licensee is an oncology company focused on the modulation of the immune system to treat cancer and is developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key.

IPSCIO Record ID: 415

License Grant
The Company acquired the intellectual property rights relating to certain combination immunogene therapy technology from Licensor, an individual.
License Property
The technology allows for making a tumor cell more recognizable by the immune system and rendering it susceptible to the cell-killing component of the immune response.

A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025.  The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the body’s immune system and destroy cancer cells.  The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF.  Our technology, which shows potential for fighting cancer by enhancing one’s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 369311

License Grant
Licensor of the Netherlands grants to Licensee of Germany a license under the Licensor Technology  to use, import, develop, market and sell and have used, imported, developed, marketed and sold product in the Field in the NA Territory and the ROW Territory.

This agreement includes a non-exclusive grant back to Licensor by Licensee.

License Property
Licensor has technology related to, inter alia, the development of BLP25.

The Product means BLP25.

BLP25 means Licensors immunotherapeutic vaccine composed of a 25-amino acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant Lipid A and is encapsulated in a liposomal delivery system, together with any improvements thereto, such as liposomal IL-2 in a kit, synthetic Lipid A, or new delivery formats such as unit dose liquid formulations and unit dose syringes.

MUC1 means cancer associated mucin-1.

L-BLP25 is a synthetic MUC1 peptide vaccine and is a biological response modifier with a chemically synthesized peptide of a cancer-associated protein antigen widely expressed on common cancers. It is designed to induce an immune response to both the synthetic antigen and the natural corresponding antigen as expressed on the cancer.

Field of Use
BLP25 Liposome Vaccine (L-BLP25) is currently in development for the treatment of non-small cell lung cancer (NSCLC).  Licensee will take over administrative and financial responsibility for the development and commercialization of L-BLP25, including the planned phase 3 trial in NSCLC

The field shall mean the use of BLP25 for the prevention and/or treatment of cancers in humans.

IPSCIO Record ID: 256328

License Grant
This amendment revises the listed patents.  Per the restated agreement, Licensor grants and agrees to grant to Licensee, upon the terms and conditions set forth in this Agreement, the exclusive rights under the Licensed Intellectual Property to make, have made, use and sell Licensed Products and Licensed Processes throughout the world and otherwise to exploit the Licensed Intellectual Property commercially throughout the world.
License Property
With this amendment, the patents are expanded and include Whole Recombinant Yeast Vaccine Activates Dendritic Cells and Elicits Protective Cell-Mediated Immunity, and, Yeast Dendritic Cell Vaccines and Uses Thereof, and, Yeast-Antigen Compositions And Methods Of Making The Same.
Field of Use
Per the restated agreement, the field of use is research and investigation for cancer therapies.

IPSCIO Record ID: 256326

License Grant
This amendment is to revise and amend the Agreement to add the Collaboration Compound known as GI-6100 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-3000 as a Drug Candidate under the Agreement.  The patents are also updated.

This amendment adds for the CRADA Research License,  Licensor grants the non-exclusive, worldwide, nontransferable and non-sublicensable license, under the Licensed Intellectual Property, solely as necessary to support research and development activities conducted by the NIH under the CRADA or Cooperative Research and Development Agreement for lntramural-PHS Clinical Research that pertain to certain Collaboration Compounds.

License Property
The candidate compounds
GI-4000 means the series of Tarmogen products that express mutated Ras and/or one or more peptides thereof. GI4014, GI-4015, GI-4016 and GI-4020 arc part of the GI-4000 series and are the subject of [IND No. BB-IND 11653].

GI-6200 means the series of Tarmogen products that solely express human carcinocmbryonic antigen (CEA). GI6207 is part of the GI-6200 series and means the single Tarmogen product that is the subject of [IND No. BB-IND 13934 (drug master file BB-MF 13884)], and that solely expresses human CEA having a N6lOD mutation.

GI-6l00 means the series of Tarmogen products that express human MUC- I antigen(s). GI-6108 is part of the GI-6l00 series and is the single Tarmogen product that is the current lead product for the GI-6100 program. GI-6108 is currently undergoing preclinical development at the National Institutes of Health under the terms of the CRADA.  As of the Amendment #5 Effective Date, GI-6l08 is believed to be the specific product intended to be subject of [an IND to be filed by the NIH under the CRADA. Should a different Tarmogen product expressing MUC-1 antigen(s), other than GI-6108, be selected for said IND], then it is understood such product shall become the Drug Candidate associated with the GI-6100 designation.

Gl-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that is the subject of [BB-IND 14895].

Field of Use
The focus of the compound in this agreement is for the treatment of cancer.
GI-4000 series target tumors with mutations in a protein called Ras.

IPSCIO Record ID: 324645

License Grant
University hereby grants to Licensee the worldwide non-exclusive right and license in the Field, with the right to sublicense subject to this agreement, to make, have made, use, sell, offer for sale and import Licensed Products and to practice under the Patent Rights until the expiration of the last to expire claim of the Patent Rights, unless this Agreement is terminated sooner as provided herein.
License Property
7,297,337 – EphA2 T-cell epitopes and uses therefor
8,114,407 – EphA2 T-cell epitopes and uses therefor
Field of Use
Field shall mean use of Licensed Product or Patent Rights in or packaged with Licensee’s Proprietary Vaccine for administration to humans for the diagnosis, prevention and treatment of diseases and tumors of the brain. For the avoidance of doubt the Field specifically excludes use of Licensed Products and/or Patent Rights in the development of therapeutic vaccines or diagnostic tests for breast, ovarian, liver, pancreatic, colon and lung cancers.

Proprietary Vaccine shall mean a vaccine which is developed or being developed for a therapeutic indication based on biological activity that is solely-owned or in-licensed by Licensee from third parties and which is not covered by the Patent Rights and which is not Licensed Product hereunder. For the avoidance of doubt, the Il-13 Alpha2 Peptide Analogues licensed under the Exclusive Patent License Agreement shall constitute a Proprietary Vaccine.

IPSCIO Record ID: 27803

License Grant
Licensor grants the Swiss Licensee, an exclusive, non-transferable  license or sublicense, as applicable, under the Licensor IP to Develop, Manufacture and Commercialize Licensed Antibodies and Products in the Territory and in the Field.

The Licensor and the Licensee formed a global alliance focused on novel immuno-therapeutics using the Licensor's proprietary Retrocyte Displayâ„¢ antibody discovery platform. The collaboration is initially focused on the development of checkpoint modulator antibodies directed against GITR, OX40, LAG-3 and TIM-3.

License Property
The Licensor is an immunology company developing a series of Checkpoint Modulators for the treatment of patients with cancer, infectious diseases, and other immune disorders, heat shock protein (HSP)-based vaccines, and immune adjuvants.

LAG-3 is a checkpoint protein expressed on the surface of certain cells of the immune system. LAG-3 (lymphocyte-activation gene 3) modulates signaling between immune cells and their targets. When LAG-3 is activated, the immune response is suppressed. Antibodies that block LAG-3 can block this inhibitory signal, thereby boosting the immune system’s response against cancer cells. LAG-3 acts synergistically with other checkpoint modulators. This suggests antibodies against LAG-3 may be valuable as combination therapies.

TIM-3 is a checkpoint receptor found on certain immune cells. TIM-3 stands for T-cell immunoglobulin and mucin domain-3. To prevent hyperactivation, natural ligands binding to TIM-3 reduce the activity of these immune cells. In some types of cancer, T cells express elevated levels of TIM-3, which results in excessive immune suppression. Blocking TIM-3 could stimulate immune responses and promote immune-mediated clearing of cancer cells. TIM-3 antibodies may have a role as a monotherapy and hold great potential in combination therapy, since they may help overcome resistance that patients may develop against other therapeutics.

[U.S. Patent Application Serial No. 62/004,071, filed May 28, 2014, entitled 'Anti-GITR Antibodies and Methods of Use Thereof.']
Field of Use
The Parties are interested in forming an alliance whose goal is to discover, develop and commercialize a robust portfolio of products to address hematologic and oncologic diseases or conditions.

Checkpoint antibodies effect the immune system, and are now being used in cancer treatment.

The Field means any use of Antibodies for the treatment, control, mitigation, prevention or cure of any or all Indications in humans or animals in the Hematology Field and the Oncology Field

IPSCIO Record ID: 7597

License Grant
Therefore the Licensor, a University, grants an exclusive license to the Licensed Patents, and an exclusive license to the Know How, to make, have made, use, import, offer to sell and sell Licensed Products and to practice the Licensed Process(es) in the Field of Use and Territory to the Licensee
Licensee may sublicense the rights granted.
License Property
The invention relates to methods for modulating the immune function through targeting of CLIP molecules.

Invention Disclosures
CU1760C- Selective Modulation of Gamma Delta T Cells to Treat Autoimmune Diseases, HIV, and Cancer
CU1969C – Competitive inhibitors of Invariant Chain expression and/or ectopic CLIP binding
CU1971C- Use of soluble H-2M (HLA-DM) as a CLIP displacement therapy (combined with CU1969C and patents filed under CU1969C)
CU2131C- Topical HIV prevention cream/gel (provisional application was abandoned as it was covered under applications filed in CU1760C and CU1969C)
CU2253C – The use of non-specific CLIP displacing peptides to treat or prevent chronic disease mediated by infectious organisms (no patents filed yet)
CU2254C – The use of peptides derived from an infectious organism that displace CLIP in order to treat or prevent chronic conditions mediated by those very organisms (no patents filed yet)

Patent Applications
Country
Serial No
File Date
Title
lnternal ID

United States
60/886,852
01/26/2007
Methods of Modulating Immune Function Through Targeting of Invariant Chain/CD74 and Clip
CU1760C- PPA1

United States
60/906,731
03/13/2007
Immune Mechanism For The Depletion of CD4+ T Cells
CU1760H- PPA2

PCT
PCT/US2008/001097
01/28/2008
Methods of Modulating Immune Function
CU1760C- PCT1

United States
12/011,643
01/28/2008
Methods of Modulating Immune Function
CU1760C-US2

United States
12/021'118
01/28/2008
Methods of Modulating Immune Function
CU1760C-US1

United States
61/191,740
09/11/2008
The Immune Response to HIV
CU1760C- PPA3

Country
Serial No
File Date
Title
lnternal ID

United States
61/000,152
10/23/2007
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1969C- PPA1

United States
61/135,942
07/25/2008
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C- PPA2

United States
61/135,964
07/25/2008
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1996C- PPA3

United States
61/137,150
07/25/2008
Methods for Treating Viral Disorders
CU1969C-PPA4

PCT
PCT/US2008/012078
10/23/2008
Competitive Inhibitors of Invariant Chain Expression and/or Ectopic Clip Binding
CU1969C-PCT1

United States
15/508,554
07/23/2009
Methods for Treating Viral Disorders
CU1969C- US1

PCT
Pending
7/23/2009
Methods For Treating Viral Disorders
CU1969C-PCT3

PCT
Pending
7/23/2009
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C-PCT2

United States
12/508,543
7/23/2009
Clip Inhibitors and Methods of Modulating Immune Function
CU1969C-US2

United States
61/135,922
7/25/2008
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-PPA1

United States
12/508,532
7/23/2009
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-US1

PCT
Unknown
7/23/2009
Proteins for Use in Diagnosing and Treating Infection and Disease
CU2421H-PCT1

Field of Use
Field of Use means the diagnosis, detection, prevention, and treatment of any disease.

IPSCIO Record ID: 212650

License Grant
The Licensor grants to Licensee a non-exclusive, royalty-bearing license, with the right to grant sublicenses, under the Patents to Exploit the Licensed Product in the Field in the Territory and to Manufacture or have Manufactured the Compound in connection with such Exploitation of the Licensed Product.  Field shall mean the use of the Licensed Product for the prevention of infection by Hepatitis B Virus in humans.  Delivery Method for the Licensed Product shall mean intramuscular or subcutaneous delivery.
License Property
The Licensor is the owner or licensee of certain rights in proprietary technologies involving immunomodulatory oligonucleotides.

“Licensed Product” shall mean a prophylactic vaccine containing the Compound co-formulated with the Antigen for delivery by the Delivery Method. No Licensed Product(s) may be developed for the prevention, treatment or control of any cancer nor may any clinical trial be conducted with clinical endpoints of prevention, treatment or control of any cancer.

Patents Claiming Priority to Patent Application Serial No. 08/276,358

Field of Use
“Field” shall mean the use of the Licensed Product for the prevention of infection by Hepatitis B Virus in humans. The Field specifically excludes any product for the prevention of disease, indications or disorders other than Hepatitis B Virus in humans and any product for the treatment of any disease, indications or disorders.

IPSCIO Record ID: 263928

License Grant
With this amendment, the Parties revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement.
License Property
GI-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that may become the subject of [an IND filing under CRADA #02264] and that expresses a human brachyury protein.
Field of Use
The focus of the compound in this agreement is for the treatment of cancer.

IPSCIO Record ID: 237236

License Grant
Licensor grants to the Licensee of Denmark a non-exclusive, non-transferable, worldwide, royalty-bearing license, with the right to grant sublicenses, under the Licensed Technology to make, have made, sell, have sold and import Products in the Field during the Term. For avoidance of doubt, Licensee shall only have the right under the license granted to use PADRE® as part of a Product.

Licensee shall have the right to grant sublicenses.

License Property
Licensed Technology shall mean, to the extent necessary or useful for research, development, manufacture, use, sale or import of Products in the Field, all Patent Rights and Know-How, including all PADRE® Improvements.

PADRE® shall mean a peptide capable of binding antigen binding sites on major histocompatibility complex (MHC) molecules encoded by substantially all alleles of a DR locus, including, without limitation, a composition comprising a peptide recited in the claims of United States Patent Application Serial No. 08/121,101 and any patent applications, U.S., international and foreign, that derive priority from such patent application, such as continuing applications and any patents issuing therefrom. Such peptides are also referred to as pan DR binding peptides and include, without limitation, AKXV AA WTLKAAA,using the single letter designation for amino acids, wherein X is cyclohexylalanine or phenylalanine, and other peptides claimed and/or disclosed in the patent applications.

Product shall mean any product that contains, is comprised of or uses PADRE® in combination or association with any AutoVac™ Molecule.

Field of Use
Field shall mean the prevention and/or treatment of diseases or disorders in humans.

The license is to use PADRE technology for use in connection with their AutoVacâ„¢ technology for controlling autoimmune diseases.
The PADRE technology consists of a family of small (13 amino acid), synthetic proprietary molecules that are potent immunostimulants, meaning that they stimulate the immune response.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.